Short Interest in OS Therapies Incorporated (NYSEAMERICAN:OSTX) Rises By 35.6%

OS Therapies Incorporated (NYSEAMERICAN:OSTX) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 845,317 shares, a growth of 35.6% from the December 31st total of 623,422 shares. Based on an average daily volume of 931,073 shares, the days-to-cover ratio is currently 0.9 days. Approximately 2.7% of the company’s stock are short sold. Approximately 2.7% of the company’s stock are short sold. Based on an average daily volume of 931,073 shares, the days-to-cover ratio is currently 0.9 days.

OS Therapies Stock Down 1.4%

Shares of NYSEAMERICAN:OSTX traded down $0.02 during trading on Friday, hitting $1.36. The stock had a trading volume of 417,684 shares, compared to its average volume of 684,399. The company has a market capitalization of $47.89 million, a PE ratio of -1.66 and a beta of -3.79. The firm’s fifty day moving average is $1.60 and its 200 day moving average is $1.84. OS Therapies has a 12 month low of $1.12 and a 12 month high of $2.98.

OS Therapies (NYSEAMERICAN:OSTX) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter. Equities research analysts expect that OS Therapies will post -0.64 EPS for the current fiscal year.

Analysts Set New Price Targets

OSTX has been the topic of a number of research reports. D. Boral Capital reissued a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research report on Monday, January 5th. Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Lake Street Capital cut their target price on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Institutional Investors Weigh In On OS Therapies

Hedge funds have recently bought and sold shares of the business. Susquehanna International Group LLP bought a new position in shares of OS Therapies during the third quarter valued at approximately $29,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of OS Therapies in the 3rd quarter worth approximately $40,000. Ground Swell Capital LLC bought a new position in OS Therapies during the 3rd quarter valued at approximately $40,000. Bridgeway Capital Management LLC purchased a new position in OS Therapies during the second quarter valued at $47,000. Finally, XTX Topco Ltd purchased a new position in OS Therapies during the second quarter valued at $63,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.